Shukra Medtech
SHUKRAMED • Pharmaceuticals & Biotechnology
Last Price
₹84.16
Market Cap
₹3.72K Cr
Sector
Pharmaceuticals & Biotechnology
For educational/research use only. Not a recommendation to buy or sell.
At a glance
as of 2026-11-20Sector: Shukra Medtech (SHUKRAMED) is an NSE-listed company in the Pharmaceuticals & Biotechnology sector, within the Pharmaceuticals industry. NSE sector rotation chart
Sharia rating: Shukra Medtech is rated Halal by a specialist third-party provider. Full list of halal NSE stocks
Price trend
No reading
We don't have enough data to measure this for Shukra Medtech right now.
Institutional activity
Positive
Trading patterns over recent weeks show some signs of institutions buying Shukra Medtech (buying score 2/10, selling score 0/10).
Model rank
Neutral
Our model's 5-day return score puts Shukra Medtech ahead of 55% of NSE stocks. The model has low confidence in this score (10%).
Ease of trading
Low
Shares change hands easily; there are no signs of trading drying up (risk score 3/10). Volume has been below normal for 6 days.
Price vs profits
Loss-making
Shukra Medtech did not make a profit last year, so there is no profit to compare the price against.
The wider Indian market is in a crisis regime — unusually sharp moves (model 99% sure). This affects every stock's model rank.
Browse ready-made screens →Company Information
About Shukra Medtech (SHUKRAMED)
Shukra Medtech is an NSE-listed company operating in the Pharmaceuticals & Biotechnology sector, within the Pharmaceuticals industry (ISIN INE551C01044). This page brings together the quantitative research signals our models compute for SHUKRAMED: a model-estimated 1-day, 5-day and 21-day return outlook, momentum and trend indicators, institutional-activity context derived from observed trading flows, a snapshot of valuation and quality fundamentals, and the instrument's Sharia-compliance status. All figures are produced by statistical models from historical data and are intended for research and educational purposes.
To read the page, treat the model-estimated return outlook as a relative ranking signal rather than a forecast of price — higher scores reflect stronger model-estimated momentum and trend alignment, not a target or guarantee. The momentum and trend indicators describe how Shukra Medtech's recent price action compares with its own history, while the fundamentals and institutional-activity context add longer-horizon and flow-based perspective. Nothing here is investment advice, a recommendation, or a solicitation to transact; always do your own research and consult a SEBI-registered adviser before making any decision.
The "typical range" we compare a price-to-earnings multiple against is a fixed band for all NSE stocks, not a sector-specific one. Everything on this page describes what our models measured; none of it is a recommendation to do anything.